Ethan Vinodh

IR I/10 CC/1st
April 29, 2020

Meta-Cognitive Analysis Results

Year Study Method Citation Results

Sample

Study 1 2014 20 male Randomized Fetoni, Anna R et al. Curcumin treatment

adult Clinical Trial “Curcuma longa attenuated hearing loss
Wistar (curcumin) decreases in induced by cisplatin,
rats vivo cisplatin-induced increased OHC survival,
ototoxicity through heme decreased 4-HNE
oxygenase-1 induction.” expression, and increased
Otology & neurotology: HO-1 expression. This
official publication of the preclinical study
American Otological demonstrates that
Society, American systemic curcumin
Neurotology Society [and] attenuates ototoxicity and
European Academy of provides molecular
Otology and Neurotology evidence for a role of
vol. 35,5 (2014): e169-77. HO-1 as an additional
doi:10.1097/MAO.000000 mediator in attenuating
0000000302 cisplatin-induced damage.

Study 2 2016 70 Double-Blind Rahimi, Hamid Reza et al. Mean age, BMI, FBG,
type-2 Randomized “The effect of total cholesterol (TC),
diabetes Clinical Trial nano-curcumin on HbA1c, triglyceride (TG), LDL,
patients fasting blood glucose, and HDL, HbA1c, and sex
lipid profile in diabetic and had no significant
subjects: a randomized difference at the baseline
clinical trial.” ​Avicenna between the groups. In
journal of phytomedicine the Nano-curcumin
vol. 6,5 (2016): 567-577. group, a significant
decrease was found in
HbA1C, FBG, TG, and
BMI comparing results of
each subject before and
after the treatment
(p<0.05). By comparing
pre- and post-treatment
 values among the groups,
HbA1c, eAG, LDL-C,
and BMI variables
showed significant
differences (p<0.05).
These findings suggest an
HbA1c lowering effect
for Nano-curcumin in
type-2 diabetes; also, it is
partially decreasing in
serum LDL-C and BMI.

Study 3 2015 30 OSF Randomized Hazarey, Vinay K et al. The test group showed a
patients Clinical Trial “Efficacy of curcumin in 5.93 (±2.37) mm increase
the treatment for oral in mouth opening
submucous fibrosis - A compared to 2.66 (±1.76)
randomized clinical trial.” mm of the control group.
Journal of oral and In relation to the VAS
maxillofacial pathology: scale with spicy and
JOMFP​ vol. 19,2 (2015): normal food, the average
145-52. reduction was 64 (42-73)
doi:10.4103/0973-029X.1 and 77 (70.5-82) as
64524 compared to 34
(14.5-64.5) and 64
(46-75.5) respectively in
the control group. The
test group results
achieved in the treatment
span were sustained in the
follow-up (P < 0.05)
compared to the control
group which showed
statistically significant (P
< 0.05) relapse. It can be
concluded that
combination strategies for
the management of OSF
which include the
stoppage of causative ill
habits, appropriate
medicinal, and
physiotherapy
management is more
efficient than single
 therapeutic modality. It is
evident from the study
that curcumin holds good
promise in the treatment
of OSF in the future.

Study 4 2013 30 Double-Blind Ryan, Julie L et al. Standard pooled variances

Breast Randomized “Curcumin for radiation t-test showed that
Cancer Clinical Trial dermatitis: a randomized, curcumin reduced RDS at
Patients double-blind, end of treatment
placebo-controlled clinical compared to placebo
trial of thirty breast cancer (mean RDS = 2.6 vs. 3.4;
patients.” ​Radiation P = 0.008). Fisher's exact
research​ vol. 180,1 test revealed that fewer
(2013): 34-43. curcumin-treated patients
doi:10.1667/RR3255.1 had moist desquamation
(28.6% vs. 87.5%; P =
0.002). No significant
differences were observed
between arms for
demographics,
compliance, radiation
skin dose, redness, pain,
or symptoms. In
conclusion, oral
curcumin, 6.0 g daily
during radiotherapy,
reduced the severity of
radiation dermatitis in
breast cancer patients.

Study 5 2015 45 Single-Blind Paschoal, Marco Aurélio No significant difference

Adolesce Randomized et al. “Longitudinal effect was found to PI between
nt Clinical trial of the groups during the
Orthodo curcumin-photodynamic baseline and 1-month
ntic antimicrobial period. Group III (1.52 ±
Patients chemotherapy in 0.51) presented a
adolescents during fixed significance difference
orthodontic treatment: a from the group I (0.91 ±
single-blind randomized 0.75) and group II (1.03 ±
clinical trial study.” 0.51) at 3 months of
Lasers in medical science follow-up. In this same
vol. 30,8 (2015): 2059-65. period, there was more
doi:10.1007/s10103-014-1 plaque accumulation with
700-7 a significant statistical
difference (P ≤ 0.05) in
comparison to the other
periods to all studied
groups. There was a GBI
reduction statistically
significant to groups I and
III at a 1-month follow-up
in comparison to other
periods. No effect was
verified to dental plaque
accumulation after the
photodynamic application
mediated with curcumin
activated with a blue LED
light.